Search PubMed⌕ Search

Biomedical subjects

D J Straus

Publications and source records attributed to D J Straus.

78 records · Page 5Linked to original sources
PubMed1979

The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis.

Measurement of cellular DNA content by flow cytometry demonstrated presence of two distinct aneuploid neoplasms in a patient who developed acute myeloblastic leukemia (AML) 4 mo after diagnosis of a diffuse histiocytic lymphoma (DHL). A lymph node aspirate contained peroxidase-negative, "null," hyperdiploid (2.6C) DHL cells, while the bone marrow (BM) contained 84% primitive peroxidase-positive tetraploid AML cells (4.0C). Minor populations of hyperdiploid HDL and normal diploid cells could be detected by flow-cytometry in the BM, and all three populations were also seen in the peripheral blood.

Adult↗
PubMed1977

Cicatricial ectropion secondary to 5-fluorouracil therapy.

Four cases of cicatricial ectropion secondary to prolonged systemic administration of 5-fluorouracil are described. In 1 patient ectropion resolved with conservative treatment and discontinuation of 5-FU. Another patient developed the ectropion terminally and died before its resolution. In 2 patients surgical repair of the ectropion was unsuccessful in relieving conjunctival symptoms while 5-FU was continued. With prolonged adjuvant chemotherapy programs utilizing 5-FU, this complication may be seen with increasing frequency. Conservative management should be attempted, and patients with this problem should be reassured that symptoms will resolve when 5-FU is stopped.

Aged↗
PubMedDate not supplied

Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.

A disease-oriented trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide) given once every 3 weeks was undertaken in patients with advanced non-Hodgkin's lymphoma. None of 15 adequately treated patients achieved complete or partial remissions. Toxicity was mild-to-moderate, consisting of myelosuppression (principally granulocytopenia) and malaise. The lack of any major responses in this number of patients suggests that, in this schedule, the drug is not useful in therapy for advanced non-Hodgkin's lymphoma.

Adult↗
PubMedDate not supplied

Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: an analysis of prognostic factors in two chemotherapy trials and the literature.

The results of two intensive combination chemotherapy trials for heavily pretreated patients with Hodgkin's disease were markedly different. Only one of 27 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) achieved a complete remission (CR), while a CR was attained by 50% of the patients (nine of 18) treated with ABVD alternating with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP/ABVD). There was a significantly longer survival for patients on MOPP/ABVD. Characteristics of patients in the two trials which might have at least partially explained these differing results were identified. The patients treated with ABVD all had prior histories of multiple relapses or continuous disease activity, while the majority of responding patients treated with MOPP/ABVD had few prior relapses and long disease-free intervals immediately prior to treatment. In the MOPP/ABVD trial, a trend toward a higher CR rate was found for patients with relapses confined to lymph nodes, compared with patients who had extranodal disease, although the difference lacked statistical significance. The characteristics of the patient population undergoing treatment must be considered in the interpretation of the results of chemotherapy salvage regimens for Hodgkin's disease.

Adult↗